KEMTUB012-NI2, a novel potent tubulysin analog that selectively targets hypoxic cancer cells and is potentiated by cytochrome p450 reductase downregulation

KEMTUB012-NI2, a novel potent tubulysin analog that selectively targets hypoxic cancer cells and is potentiated by cytochrome p450 reductase downregulation

Paolo Lazzari,1 Marco Spiga,1 Monica Sani,1,2 Matteo Zanda,2,3 Ian N Fleming4 1KemoTech s.r.l., Parco Scientifico della Sardegna, Pula, Cagliari, 2C.N.R. – Istituto di Chimica del Riconoscimento Molecolare, Sezione ‘A. Quilico’, Milano, Italy; 3Kosterlitz Centre for The...

Full description

Bibliographic Details
Main Authors: Lazzari P, Spiga M, Sani M, Zanda M, Fleming IN
Format: Article
Language:English
Published: Dove Medical Press 2017-05-01
Series:Hypoxia
Subjects:
breast cancer
tubulysin
anti-mitotic
hypoxia
cell death
reductase
Online Access:https://www.dovepress.com/kemtub012-ni2-a-novel-potent-tubulysin-analog-that-selectively-targets-peer-reviewed-article-HP

Internet

https://www.dovepress.com/kemtub012-ni2-a-novel-potent-tubulysin-analog-that-selectively-targets-peer-reviewed-article-HP

Similar Items